These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2045131)

  • 1. Characterization of C1 inhibitor binding to neutrophils.
    Chang NS; Boackle RJ; Leu RW
    Immunology; 1991 May; 73(1):95-101. PubMed ID: 2045131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of sialic acid in the functional activity and the hepatic clearance of C1-INH.
    Minta JO
    J Immunol; 1981 Jan; 126(1):245-9. PubMed ID: 7451969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of C1 esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli O157:H7.
    Lathem WW; Bergsbaken T; Welch RA
    J Exp Med; 2004 Apr; 199(8):1077-87. PubMed ID: 15096536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C1 inhibitor-C1s complexes are internalized and degraded by the low density lipoprotein receptor-related protein.
    Storm D; Herz J; Trinder P; Loos M
    J Biol Chem; 1997 Dec; 272(49):31043-50. PubMed ID: 9388254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The structural basis for neutrophil inactivation of C1 inhibitor.
    Pemberton PA; Harrison RA; Lachmann PJ; Carrell RW
    Biochem J; 1989 Feb; 258(1):193-8. PubMed ID: 2930506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A surface-bound form of human C1 esterase inhibitor improves xenograft rejection.
    Matsunami K; Miyagawa S; Yamada M; Yoshitatsu M; Shirakura R
    Transplantation; 2000 Mar; 69(5):749-55. PubMed ID: 10755521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface-bound capsular polysaccharide of type Ia group B Streptococcus mediates C1 binding and activation of the classic complement pathway.
    Levy NJ; Kasper DL
    J Immunol; 1986 Jun; 136(11):4157-62. PubMed ID: 3517165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A solid-phase antibody capture assay for the measurement of C1-inhibitor consumption in vivo.
    Wallace EM; Feighery C; Jackson J
    Scand J Clin Lab Invest; 1996 Feb; 56(1):1-9. PubMed ID: 8850166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The critical concentration of C1-esterase inhibitor (C1-INH) in human serum preventing auto-activation of the first component of complement (C1).
    Windfuhr JP; Alsenz J; Loos M
    Mol Immunol; 2005 Apr; 42(6):657-63. PubMed ID: 15781109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro interaction of C1-inhibitor with thrombin.
    Cugno M; Bos I; Lubbers Y; Hack CE; Agostoni A
    Blood Coagul Fibrinolysis; 2001 Jun; 12(4):253-60. PubMed ID: 11460008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α1-Antichymotrypsin Present in Therapeutic C1-Inhibitor Products Competes with Selectin-Sialyl LewisX Interaction.
    Engel R; Delvasto-Nuñez L; Roem D; van Mierlo G; Holst S; Hipgrave Ederveen AL; van Buul JD; Wuhrer M; Wouters D; Zeerleder S
    Thromb Haemost; 2018 Dec; 118(12):2134-2144. PubMed ID: 30453343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteolytic inactivation of plasma C1- inhibitor in sepsis.
    Nuijens JH; Eerenberg-Belmer AJ; Huijbregts CC; Schreuder WO; Felt-Bersma RJ; Abbink JJ; Thijs LG; Hack CE
    J Clin Invest; 1989 Aug; 84(2):443-50. PubMed ID: 2668333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degradation of C1-inhibitor by plasmin: implications for the control of inflammatory processes.
    Wallace EM; Perkins SJ; Sim RB; Willis AC; Feighery C; Jackson J
    Mol Med; 1997 Jun; 3(6):385-96. PubMed ID: 9234243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and functional aspects of C1-inhibitor.
    Bos IG; Hack CE; Abrahams JP
    Immunobiology; 2002 Sep; 205(4-5):518-33. PubMed ID: 12396012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure and function of C1 inhibitor.
    Davis AE
    Behring Inst Mitt; 1989 Jul; (84):142-50. PubMed ID: 2679529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy.
    Hack CE; Ogilvie AC; Eisele B; Jansen PM; Wagstaff J; Thijs LG
    Prog Clin Biol Res; 1994; 388():335-57. PubMed ID: 7831367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma C1 inhibitor in malignant diseases: functional activity versus concentration.
    Starcević D; Jelić-Ivanović Z; Kalimanovska V
    Ann Clin Biochem; 1991 Nov; 28 ( Pt 6)():595-8. PubMed ID: 1776810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.
    Eldering E; Huijbregts CC; Nuijens JH; Verhoeven AJ; Hack CE
    J Clin Invest; 1993 Mar; 91(3):1035-43. PubMed ID: 8450033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of the proteolytic activity of mouse nerve growth factor by human C1(activated)-inhibitor.
    Faulmann EL; Young M; Boyle MD
    J Immunol; 1987 Jun; 138(12):4336-40. PubMed ID: 3295045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C1-inhibitor--biochemical properties and clinical applications.
    Al-Abdullah IH; Greally J
    Crit Rev Immunol; 1985; 5(4):317-30. PubMed ID: 3899511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.